Clinician Article
Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.
PMID: 36623286
-
Family Medicine (FM)/General Practice (GP)Relevance - 7/7
Newsworthiness - 6/7 -
General Internal Medicine-Primary Care(US)Relevance - 7/7
Newsworthiness - 6/7 -
EndocrineRelevance - 6/7
Newsworthiness - 5/7 -
NephrologyRelevance - 6/7
Newsworthiness - 5/7 -
Pediatrics (General)Relevance - 6/7
Newsworthiness - 5/7 -
Internal MedicineRelevance - 5/7
Newsworthiness - 6/7
Abstract
DESCRIPTION: The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease is an update of the 2020 guideline from Kidney Disease: Improving Global Outcomes (KDIGO).
METHODS: The KDIGO Work Group updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the Work Group used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and expert judgment to develop consensus practice points. New evidence led to updating of recommendations in the chapters Comprehensive Care in Patients With Diabetes and CKD (Chapter 1) and Glucose-Lowering Therapies in Patients With T2D and CKD (Chapter 4). New evidence did not change recommendations in the chapters Glycemic Monitoring and Targets in Patients With Diabetes and CKD (Chapter 2), Lifestyle Interventions in Patients With Diabetes and CKD (Chapter 3), and Approaches to Management of Patients With Diabetes and CKD (Chapter 5).
RECOMMENDATIONS: The updated guideline includes 13 recommendations and 52 practice points for clinicians caring for patients with diabetes and chronic kidney disease (CKD). A focus on preserving kidney function and maintaining well-being is recommended using a layered approach to care, starting with a foundation of lifestyle interventions, self-management, and first-line pharmacotherapy (such as sodium-glucose cotransporter-2 inhibitors) demonstrated to improve clinical outcomes. To this are added additional drugs with heart and kidney protection, such as glucagon-like peptide-1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists, and interventions to control risk factors for CKD progression and cardiovascular events, such as blood pressure, glycemia, and lipids.
Clinical Comments
Endocrine
Useful guidelines for nephrologists that closely mirror clinical practice guidelines for diabetes management that were published in the past 2-3 years.
Endocrine
As an endocrinologist, I appreciate the joint efforts of multiple subspecialists to treat the whole patient and not just the plasma glucose level. This is a great advance.
Internal Medicine
Updated KIGO guideline.
Internal Medicine
Useful packaging of available evidence, but very limited incorporation of cost-effectiveness data.
Nephrology
This is a nice concise summary of the extensive KDIGO practice guidelines for diabetic nephropathy. This is broadly applicable to any clinical nephrologist and to many general internists. The figures and schema are well done and useful. Overall, a very high-yield summary.
Nephrology
An informative paper.
Pediatrics (General)
The new KDIGO Guidelines incorporate the newest therapeutic management in diabetes, chronic kidney disease, and heart disease prevention. These guidelines may not be directly relevant to young children, but are definitely helpful in transitioning pediatric patients to adulthood.
Register for free access to all Professional content
RegisterOur Content
About
Support for the Portal is largely provided by the Labarge Optimal Aging Initiative. AGE-WELL is a contributing partner. Help us to continue to provide direct and easy access to evidence-based information on health and social conditions to help you stay healthy, active and engaged as you grow older. Donate Today.
